Facebook (FB) has made several patent applications for technology that would tap into users’ historical location data as well as other data points to predict their next moves. Although the company says its patent applications aren’t a proper gauge of its future plans because it often seeks patents for technology it never implements, the technology seems like it could be useful to Facebook in many ways.
Q1 2024 Quantumscape Corp Earnings Call
Merck & Co on Thursday raised its annual profit and revenue forecast on the back of strong sales for its blockbuster cancer drug Keytruda. The New Jersey-based drugmaker said it expected earnings of $8.53 and $8.65 per share, up from its previous forecast of $8.44 to $8.59, and sales of $63.1-$64.3 billion for the year. Merck's new forecast includes a $0.26 per share charge for its $680 million acquisition of cancer drug developer Harpoon Therapeutics, which closed in the first quarter of 2024, the company said.
Matty Healy "hasn't listened to much" of Taylor Swift's new album. The 35-year-old singer briefly dated pop megastar Taylor, 34, in 2023 and she is thought to have used several of her relationships as inspiration for her new 30-track album 'The Tortured Poets Department' but when asked about a certain "diss track" that is supposedly about him, he admitted he hasn't even really listened to the record yet. He told 'Entertainment Tonight:': "My diss track? I haven’t really listened to that much of
Revenue from its financial technology unit surged 71% to $392 million in the first quarter, while revenue from its index business jumped 53% to $168 million. Nasdaq, like its peers, has been on an acquisition spree to diversify its portfolio of technology and intellectual property after regulations in 2005 opened the equities trading market up to competition from brokers. Net revenue in the first quarter jumped 22% to $1.12 billion.
Global Business Process Management Market Global Business Process Management Market Dublin, April 25, 2024 (GLOBE NEWSWIRE) -- The "Global Business Process Management Market by Component (Services, Solution), Deployment (Cloud, On-Premise), Application - Forecast 2024-2030" report has been added to ResearchAndMarkets.com's offering. The Business Process Management Market size was estimated at USD 4.40 billion in 2023, USD 4.74 billion in 2024, and is expected to grow at a CAGR of 7.69% to reach
West Pharmaceutical Services on Thursday beat quarterly profit estimates and raised its annual profit forecast, banking on rising demand for cartridges and syringes used to manufacture injectable therapies. The company expects sales growth to ramp up as the year progresses, partly due to a surge in demand for components used in the packaging of newer treatments, including Novo Nordisk's diabetes drug Ozempic, weight-loss drug Wegovy, and Eli Lilly's diabetes drug Mounjaro. CEO Eric Green said that he expects a majority of sales growth to take place in the second half, as biotech clients work through their existing inventory.
Q1 2024 Chipotle Mexican Grill Inc Earnings Call
Robert, 82, makes a surprise cameo in Chris' directorial debut "Poolman"
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Nasdaq, Inc. (Nasdaq: NDAQ) has declared a regular quarterly dividend of $0.24 per share on the company's outstanding common stock, a 9% increase from the previous quarter. The dividend is payable on June 28, 2024 to shareholders of record at the close of business on June 14, 2024. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to approval by the Board of Direct
Dublin, April 25, 2024 (GLOBE NEWSWIRE) -- The "2024 EMEA Merchant POS/mPOS Software ISV List With Marketshare" report has been added to ResearchAndMarkets.com's offering. This product is a list of over 180 top POS ISVs (independent software vendors) in the EMEA POS and mPOS markets for merchants and retailers. It is inclusive of those that make their own POS equipment like NCR, Oracle, Oracle/MICROS, Fujitsu and others, as well as pure software players like Aptos, OneView Commerce, and others.
Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligned with FDA feedback HB-200 accepted for oral abstract presentation at ASCO 2024 Annual Meeting with data from approximately 40 patients treated with HB-200 in combination with pembrolizumab Two additional abstracts for HB-200 and HB-700 accepted for the ASCO 2024 Annual Meeting Company to host investor call at 8:00 a.m.
Q1 2024 Century Communities Inc Earnings Call
According to LendingTree, the average monthly car payment for new vehicles is $738 -- higher than it's ever been. Leased and used vehicles have also gone up on a year-over-year basis, with used cars...
According to an annual retirement study conducted by Allianz Life, 63% of Americans are more concerned about running out of money than death. These fears are fueled by soaring inflation, a worry about...
Dave Ramsey approaches retirement planning with the same commonsense wisdom as the rest of this financial advice. Discover More: Cutting Expenses in Retirement: 6 Home Items to Stop BuyingRead Next:...
The much-missed restaurant will become a summer-long pop-up on Park Lane
CINCINNATI, April 25, 2024--LSI Industries Inc. (Nasdaq: LYTS, "LSI" or the "Company") a leading U.S. based manufacturer of commercial lighting and display solutions, today reported financial results for the fiscal 2024 third quarter ended March 31, 2024.
The dry eye treatment devices market size is anticipated to grow from USD 309.96 Million in 2023 to USD 632.91 Million in 10 years. The market ought to witness a positive growth rate owing to increasing prevalence of dry eye disorders in developed countries.Newark, April 25, 2024 (GLOBE NEWSWIRE) -- The Brainy Insights estimates that the global dry eye treatment devices market will grow from USD 309.96 Million in 2023 to USD 632.91 Million by 2033. Technological trends have resulted in the creat
NEW YORK, April 25, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study of MM120 in Generalized Anxiety Disorder (GAD), as well as multiple presentations describing the epidemiology and growing burden of GAD at two upcoming medical conferences:
Yahoo Finance